Patients From periodic medication review to proactive medication surv... As regimens, physiology, and clinical information change, medication review needs to become more responsive to those changes.
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.